🇺🇸 FDA
Patent

US 11767321

5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases

granted A61KA61K31/437A61K31/444

Quick answer

US patent 11767321 (5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases) held by Enliven Inc. expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enliven Inc.
Grant date
Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K31/437, A61K31/444, A61K31/496, A61K31/4995